GEMCITABINE THYMOORGAN 1000mg Price

Overview

Welcome to Dwaey, specifically on GEMCITABINE THYMOORGAN 1000mg Infusion/Powder for Solution for page.
This medicine contains an important and useful components, as it consists of Gemcitabine.
GEMCITABINE THYMOORGAN 1000mg is available in the market in concentration 1000mg/Vial and in the form of Infusion/Powder for Solution for.

HIKMA PHARMACEUTICALS is the producer of GEMCITABINE THYMOORGAN 1000mg and it is imported from JORDAN, The most popular alternatives of GEMCITABINE THYMOORGAN 1000mg are listed downward .

Mode Of Action

Gemcitabine is a synthetic pyrimidine nucleoside and cytarabine analogue which is metabolised intracellularly to active diphosphate and triphosphate nucleosides. It inhibits DNA synthesis by inhibiting DNA polymerase and ribonucleotide reductase. It also induces apoptosis and is primarily active against cells in the S-phase, but may also arrest cells at the G1-S border.

Indication

• Lung cancer
• pancreatic cancer
• bladder cancer
• breast cancer
• ovarian carcinoma

Precaution

Children, hepatic and renal impairment. May impair ability to drive or operate machinery. Discontinue on 1st sign of microangiopathic haemolytic anaemia. Prolonged infusion time (>60 minutes) and more frequent than wkly dosing may increase toxicity. Monitor CBC before every dose. Increased risk of haemolytic uraemic syndrome and/or thrombocytcpenic purpura which may lead to irreversible renal failure. Lactation: not known if excreted in breast milk; do not nurse

Side Effects

• >10% N/V (69%)
• Anemia (65%)
• Elev LFTs (68%)
• Neutropenia (63%)
• Leukopenia (62%)
• Pain (48%)
• Proteinuria (45%)
• Fever (41%)
• Hematuria (35%)
• Rash (30%)
• Thrombocytopenia (24%)
• Dyspnea (23%)
• Constipation (23%)
• Diarrhea (19%)
• Flu-like syndrome (19%)
• Hemorrhage (17%)
• BUN increased (16%)
• Infection (16%)
• Alopecia (15%)
• Edema (13%)
• Elev bilirubin (13%) 1-10% Paresthesia (2-10%)
• Creatinine increased (2-8%)
• Inj site reactions (4%)
• Bronchospasm (2%) Potentially Fatal: Oesophagitis and pneumonitis when given with radical radiotherapy to the thorax.

Contra indication

Concurrent radical radiotherapy; pregnancy, lactation; hypersensitivity.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.